Brief: Blueprint Medicines Reports Fourth Quarter And Full Year 2022 Results

Blueprint Medicines

16/02/2023 12:39

Feb 16 (Reuters) - Blueprint Medicines Corp  BPMC.O :
    * BLUEPRINT MEDICINES REPORTS FOURTH QUARTER AND FULL YEAR
2022
RESULTS
    * Q4 REVENUE $204.0 MILLION
    * QTRLY LOSS PER SHARE $2.65
    * ANTICIPATES ABOUT $130 MILLION TO $140 MILLION IN AYVAKIT
NET
PRODUCT REVENUES FOR ADVANCED SM AND GIST IN 2023
    * Q4 EARNINGS PER SHARE VIEW $-2.65, REVENUE VIEW $34.4
MILLION --
REFINITIV IBES DATA

Source text for Eikon:  ID:nPn9DHj17a 
Further company coverage:  BPMC.O 
 ((Reuters.Briefs@thomsonreuters.com;;))